Brolucizumab ─ Termination of 4 weekly trials ─ Rebalancing the Immunogenicity Risk

Expert Opinion on Biological Therapy ◽

10.1080/14712598.2022.2028772 ◽

2022 ◽

Author(s):

Ashish Sharma ◽

Nilesh Kumar ◽

Nikulaa Parachuri ◽

Jean-Yves Sahyoun ◽

Baruch D Kuppermann ◽

...

Download Full-text